Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AA36
|
| gptkbp:contraindication |
active hepatitis B infection
|
| gptkbp:cost |
high
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
immunosuppressant
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:ocrelizumab
|
| gptkbp:halfLife |
26 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ocrevus
|
| gptkbp:indication |
primary progressive multiple sclerosis
relapsing multiple sclerosis |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:mechanismOfAction |
anti-CD20 monoclonal antibody
|
| gptkbp:patentExpired |
2029 (US)
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.ocrevus.com
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
rash infusion reactions decreased immunoglobulins |
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|